CXCR7 GPCR insurmountable antagonist target engagement in rodent, 61% F in dog from 300k HTS vs. β-arrestin recruitment, opt. J. Med. Chem., Dec. 14, 2020 Idorsia Pharma (Actelion), Allschwil, CH